UCB

CNS DiseasesImmunologicals

UCB

Belgium-based UCB (Euronext Brussels: UCB) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Belgium-based UCB (Euronext Brussels: UCB) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

It is focused on CNS diseases, such as epilepsy, ADHD, memory problems, narcolepsy, Parkinson's disease and restless legs syndrome (RLS), and immunology such as allergies, ankylosing spondylitis, Crohn's disease, juvenile rheumatoid arthritis and RA, osteoporosis, psoriatic arthritis, respiratory disorders, rheumatoid arthritis and systemic lupus (SLE). Lead drugs include Cimzia (certolizumab pegol), Vimpat (lacosamide), Neupro (rotigotine) and Keppra (levetiracetam).


Latest Articles

Who's Who

Back to top